Loading clinical trials...
Loading clinical trials...
A Prospective Randomized Controlled Clinical Study of Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
Conditions
Interventions
DAG pre-excitation regimen with Bortezomib
Locations
1
China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Start Date
January 1, 2020
Primary Completion Date
September 1, 2023
Completion Date
December 1, 2023
Last Updated
August 9, 2023
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06994676
NCT06484062
Lead Sponsor
Zhongnan Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions